| Caitlin Elizabeth Blumhardt, LPN | |
|
2087 S Forman Rd, Baldwin, MI 49304-9533 | |
| (517) 442-7172 | |
| Not Available |
| Full Name | Caitlin Elizabeth Blumhardt |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 2087 S Forman Rd, Baldwin, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194314781 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 4703112094 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Caitlin Elizabeth Blumhardt, LPN 2087 S Forman Rd, Baldwin, MI 49304-9533 Ph: (517) 442-7172 | Caitlin Elizabeth Blumhardt, LPN 2087 S Forman Rd, Baldwin, MI 49304-9533 Ph: (517) 442-7172 |
News Archive
The Wall Street Journal reports on how "a reportedly fake vaccination campaign conducted by the U.S. to help hunt down Osama bin Laden has caused a backlash against international health workers in some parts of Pakistan and has impeded efforts to wipe out polio in the country," one of only four worldwide where polio remains endemic.
Synergetics has announced that it has received an additional patent covering its bipolar technology through the issuance of U.S. patent number 7,041,096.
American researchers from the Institute for Biomedical Sciences at Georgia State University have found that certain foods such as cheese, cookies, French fries, energy drinks, soda, and other types of junk foods are found more frequently in the diets of adults suffering from inflammatory bowel disease (IBD).
Starting antiretroviral therapy early not only prevents serious AIDS-related diseases, but also prevents the onset of cancer, cardiovascular disease, and other non-AIDS-related diseases in HIV-infected people, according to a new analysis of data from the Strategic Timing of AntiRetroviral Treatment (START) study, the first large-scale randomized clinical trial to establish that earlier antiretroviral treatment benefits all HIV-infected individuals.
Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the Company has been selected to present key Tovaxin data at the upcoming American Academy of Neurology 63rd Annual Meeting to be held in Honolulu, Hawaii April 9-16, 2011.
› Verified 4 days ago